[1] SIEGEL R L, WAGLE N S, CERCEK A, et al. Colorectal cancer statistics, 2023[J]. CA A Cancer J Clinicians, 2023, 73(3): 233-254. doi:  10.3322/caac.21772
[2] 张宜利, 李巍. 结直肠癌肝转移转化治疗进展[J]. 腹部外科, 2021, 34(4): 322-326. doi:  10.3969/j.issn.1003-5591.2021.04.016
[3]

LI J, QIN S K, XU R H, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial[J]. JAMA, 2018, 319(24): 2486-2496. doi:  10.1001/jama.2018.7855
[4] 郭芬, 时建明, 张璐瑶, 等. 呋喹替尼治疗转移性结直肠癌的真实世界观察[J]. 实用肿瘤杂志, 2024, 39(1): 40-45.
[5] 胡浪, 林小玲, 唐文军. 呋喹替尼单药及联合PD-1抑制剂用于晚期转移性结肠癌后线治疗的疗效及安全性[J]. 实用医学杂志, 2023, 39(15): 1966-1973. doi:  10.3969/j.issn.1006-5725.2023.15.019
[6]

XU R H, LI J, BAI Y X, et al. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase Ⅱ study[J]. J Hematol Oncol, 2017, 10(1): 22. doi:  10.1186/s13045-016-0384-9
[7]

ZHAO J, YAN D M, LI Y, et al. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2024, 1237: 124100. doi:  10.1016/j.jchromb.2024.124100
[8] 温州医科大学附属第一医院. 一种快速检测大鼠血浆中呋喹替尼的UPLC-MS/MS方法[P]. 中国, 201910539488.8 . 2019-08-27.